Moderna’s shares rallied after the biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial. In early trading, the shares were 4.3% higher at $28.34, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results